Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Netazepide - Trio Medicines

Drug Profile

Netazepide - Trio Medicines

Alternative Names: sograzepide; YF 476

Latest Information Update: 29 Nov 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Astellas Pharma; Trio Medicines
  • Developer Ferring Pharmaceuticals; Trio Medicines
  • Class Antibacterials; Antineoplastics; Antiulcers; Benzodiazepines; Phenylurea compounds; Pyridines; Small molecules
  • Mechanism of Action Cholecystokinin B receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Neuroendocrine tumours
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Barrett's oesophagus; Neuroendocrine tumours
  • Discontinued Gastro-oesophageal reflux; Helicobacter infections; Peptic ulcer; Reflux oesophagitis

Most Recent Events

  • 29 Nov 2022 Netazepide is still in phase-II trials for Neuroendocrine tumours in USA (Trio Medicines pipeline, November 2022)
  • 03 Aug 2020 Discontinued - Phase-II for Helicobacter infections in United Kingdom (PO) (TRIO Medicines pipeline, August 2020)
  • 14 Aug 2019 Trio Medicines terminates a phase II trial due to poor recruitment in Neuroendocrine tumours (Gastric carcinoids) in USA (PO) (NCT02454075)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top